SpringRA Leads FDA Authorization for Levo Gen 2, a Software-Only Tinnitus Device
The Toronto consultancy ran the full submission - software, safety and data documentation, and FDA responses -
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.

![]()
The Toronto consultancy ran the full submission – software, safety and data documentation, and FDA responses – unlocking expanded U.S. market access.
TORONTO, CANADA, November 16, 2026 /EINPresswire.com/ — Levo Medical Corporation’s Levo Gen 2 Tinnitus Therapy System received FDA 510(k) clearance on 13 August 2026 (K260413), for adult patients seeking software-based, remote-delivered tinnitus relief. The device is a software-only treatment that can be delivered remotely. SpringRA, the Toronto regulatory consultancy, ran the authorization end to end – the software documentation, the submission, and post-submission communication with the FDA. SpringRA is the correspondent of record on the submission, with principal consultant Tal Bresler Stramer as the contact.
The first-generation Levo System was cleared in 2014 and included sound masking and dedicated hardware. The new generation was a software only device that combines two therapeutic modalities, individualized sound masking and CBT based Habituation program. The work began in September 2025 and took about a year.
What this submission entailed
The submission ran to more than 30 documents spanning cybersecurity, auditory safety and psychological safety. FDA also required that patient data stay inside Levo’s own ecosystem – processed by an AI agent Levo runs itself, rather than routed through a third-party model.
“It’s extremely complex. There were over 30 documents, from cybersecurity to auditory safety, to psychological safety – every aspect of the treatment,” said Daniel Drexler, physician and CEO of LevoMedical.
What SpringRA did
Software development lifecycle (SDLC): guided and wrote the SDLC documentation.
Cybersecurity and safety documentation: built the evidence FDA requires for premarket review, across cybersecurity, auditory safety and psychological safety.
510(k) submission: composed the submission documents.
FDA interactions: prepared the responses to FDA’s Additional Information request and facilitated a Submission Issue Request (SIR) to communicate with the agency.
Project management: coordinated work across the Levo and SpringRA teams.
SpringRA’s Tal Bresler Stramer led a multidisciplinary team of subject matter experts from Levo and SpringRA, working alongside Levo’s engineering and clinical teams.
“Working with the Levo team was a real pleasure. They combined clinical insight with engineering discipline, which is what a software-only therapy combining sound masking and CBT needs to meet FDA’s expectations. We’re proud to have helped bring a remote treatment option to adults living with tinnitus,” said Tal Bresler Stramer of SpringRA.
Opening new U.S. market opportunities
This 510(k) clearance unlocks a major strategic milestone for Levo Medical Corporation, opening access to a significantly expanded market of adult patients in the United States seeking software-based, remote-delivered tinnitus relief.
The need behind the device
Approximately 1 in 10 US adults, an estimated 21.4 million people, experience tinnitus in a given year (Bhatt JM, Lin HW, Bhattacharyya N. JAMA Otolaryngol Head Neck Surg. 2016;142(10):959–965). For many of them, tinnitus disrupts sleep, concentration and emotional wellbeing.
The full case study is at https://springra.com/articles/case-study-levo-gen-2-tinnitus-therapy-system-receives-fda-510k-clearance/.
About SpringRA
SpringRA is a Toronto-based regulatory affairs consultancy for medical device manufacturers. It supports FDA, Health Canada and EU MDR submissions, including 510(k)s and documentation for software as a medical device (SaMD).
About Levo Medical Corporation
Levo Medical Corporation develops technologies that reduce the impact of tinnitus and the distress associated with tinnitus perception.
Shifra Hoch
SpringRA
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
![]()
Media gallery
